The National Institute of Mental Health will fund up to $1.75 million per year for applications for Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research. The institute seeks teams of researchers employing integrative, novel, and creative experimental approaches to address high-risk, high-impact questions in basic neuroscience or translational research with the primary objectives of: (a) advancing the state of the science in basic brain and behavior research that will ultimately provide the foundation for understanding mental disorders; (b) supporting the integration and translation of basic and clinical neuroscience research on severe mental illnesses; and/or (c) advancing our understanding of the neurobehavioral mechanisms that begin in childhood and adolescence.
The National Cancer Institute will award $400,000 per year for up to five years for projects that develop state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology. The projects supported by this FOA will establish and collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program.
NIH’s, the ITM’s parent organization, National Institute on Aging and National Cancer Institute will fund research projects that increase our understanding of the clinical translational potential of metformin to delay aging changes or to extend healthy human life span. This includes identification of specific populations particularly likely to benefit from treatment, and/or obtaining information on metformin’s effects that would be useful in identifying novel molecular targets.
The NIH’s National Institute on Aging will award $40,000 per year to applications from qualified researchers to acquire training and career development experiences that close expertise gaps in data science and in drug discovery. The goal of the program is to allow Alzheimer’s Disease (AD) researchers to expand their expertise to become more effective in leading cross-disciplinary, translational, team-science projects in AD research.
Source: National Institute on Aging
Translating biomedical discoveries into real-world applications is essential to improving human health. It’s a complex process that can result in delays of years or decades before improved patient outcomes result from discoveries in biomedical research – and NCATS wants solutions. NCATS’ (the ITM’s parent organization) spurs the development, demonstration, and dissemination of innovations across the translational science spectrum to turn discoveries from the laboratory into tangible benefits to human health. NCATS’s Clinical and Translational Science Award (CTSA) hubs, like the ITM, promote advances in translational research and training at participating institutions.
This funding opportunity funds up to $275,000 to new exploratory and developmental research projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on translational science. This grant will enable collaborative teams of investigators from at least two different CTSA institutions to address translational science questions. Collaborations that bring together approaches from different scientific disciplines are encouraged.
NCATS will fund up to $500,000 per year for projects that support testing new therapeutic uses for experimental drugs across a broad range of pediatric diseases. This innovative program allows investigators to propose new therapeutic uses for drugs from pharmaceutical company partners. Strong applications will include scientific evidence that your drug repurposing will have a positive impact on the disease/condition.
Source: NIH NCATS
The NIH’s National Cancer Institute (the NIH is the parent organization of the ITM) will fund $4 million to approximately 10 exploratory projects that develop or validate emerging technologies that contribute to targeting, probing, or assessing molecular and cellular features of cancer biology. Projects should show potential to improve cancer biology research, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities.
Source: National Cancer Institute
The NIH’s National Cancer Institute (the NIH is the parent organization of the ITM) will fund $4 million to approximately 10 exploratory projects focused on the inception and early-stage development of innovative molecular and cellular analysis technologies. Projects should show potential to improve cancer biology research, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities.
Source: National Cancer Institute
The NIH’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants fund small businesses and research organizations whose work benefits the public. The annual SBIR & STTR Omnibus Solicitation, released by the Department of Health and Human Services, accept investigator-initiated grant applications across a broad range of research areas. Eligible small businesses should have the capabilities and technology to contribute to the mission of the awarding NIH Institute or Center.
The NIH will fund up to $300,000 to projects that support testing new therapeutic uses for experimental drugs across a broad range of human diseases. This innovative program allows investigators to propose new therapeutic uses for Assets from pharmaceutical company partners. Strong applications will include scientific evidence that modulation of an Assets target should have a positive impact on the disease/condition. Submit a pre-application first.